CMS Focuses on E-Prescribing


By Neil Versel, contributing editor

October 7, 2008 | BOSTON—With less than three months to go before Medicare starts paying incentives to physicians for electronic prescribing, the Centers for Medicare and Medicaid Services (CMS) is working frantically to get the word out about the benefits of such technology.

At least 1,400 people are gathering in a Boston hotel today for a whirlwind conference intended to tout the incentives and raise awareness among doctors, pharmacists, practice administrators, IT staff, vendors, and others who might have a role in e-prescribing before the program starts Jan. 1.

Acting CMS administrator Kerry Weems says Congress included “one very small but very valuable gift,” namely the e-prescribing financial incentives, buried deep in the Medicare Improvements for Patients and Providers Act that passed—over the president’s veto—in July. (See “Medicare Legislation Provides Incentives for ePrescribing.”)

The program will provide physicians with 2 percent bonus payments on top of regular Medicare fees in 2009-10, then a 1 percent bonus in 2011-12, followed by 0.5 percent in 2013. Starting in 2012, CMS will start docking providers 1 percent for failing to e-prescribe, a penalty that rises to 1.5 percent in 2013 and 2 percent in 2014. This money is in addition to the 2 percent bonuses doctors can earn for participating in the Physician Quality Reporting Initiative program.

CMS estimates that Medicare could save $156 million over the five-year life of the program through error prevention and efficiency improvements, but that figure is based on the 6 percent of physicians said to have e-prescribing systems at the end of 2007. That number now is around 8 percent and rising, according to CMS. “Our goal for this conference is to make [the savings] very different from those estimates,” Weems says.

“The key message of this conference is that you can’t qualify for the bonus if you don’t have an e-prescribing system,” says CMS chief medical officer Barry Straube.

David Brailer, the former national health-IT czar who now runs investment firm Health Evolution Partners (San Francisco) calls e-prescribing “bite-sized in terms of what physicians need to change and do,” something that help doctors make the first step toward adopting full electronic health records.

“You won’t go wrong investing your time and money,” says Brailer, whose company chose e-prescribing vendor Prematics as the recipient of one of its first investments.

“What’s the thin end of the spear? What’s the thing that really drives this into physician offices?” Brailer believes e-prescribing is the answer, and that bonus payments are the enticement. “Doctors are never sure what to focus their time on, so they do follow the money,” Brailer says.

 “Our theme is accelerated adoption of this technology,” Weems says. CMS put the conference together in just six weeks, even including continuing medical education credit for physicians. “This conference is meant to jump-start that process,” Weems adds. “It’s about kicking down barriers and stepping on the accelerator for the next couple of months.”

CMS promises a final rule in November as part of the 2009 Medicare Part B fee schedule, to include a definition of “successful” e-prescribing, as well as the CPT codes which are eligible for the bonuses. “We wanted to hold the conference before [the rule comes out] to get a sense of where the industry stands,” Weems says.

“I think these Medicare incentives will go a long way in terms of overcoming some of these barriers,” says Jeffrey Smith, vice president for strategy and business development at pharmacy chain and pharmacy benefits manager CVS Caremark (Woonsocket, R.I).

 

 

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Life Science Webcasts & Podcasts

medidata podcast #8 Meeting Today’s Challenges in Clinical Trial Supply Management
Sponsored by: Medidata Solutions Worldwide  

Setting up and managing the clinical trial involves many complex procedures. Among the most challenging are planning and executing the logistics of the trial’s clinical supplies. This podcast focuses in depth on the following topics which trace current practices and future evolution of this crucial aspect of clinical trials:

  • Current practices in clinical trial logistics
  • Comparing advances in clinical supply practices to  other aspects of clinical trials 
  • Where current practices fall short of meeting the challenges
  • Trends and evolving improvements that may change the way logistics are conducted

Listen Now  


More Podcasts

Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .